In particular, the epidermal growth factor receptors (EGFR) showed overexpressions in prostate or breast cancers; therefore, EGFR acts as a potential candidate for targeting the gene complexes at cancer sites [88]. This evidence concerns the gene EGFR and breast carcinoma.